(189 days)
The ADVIA® Chemistry Hemoglobin A1c method is for in vitro diagnostic use in the quantitative determination of Hemoglobin A1c, a diabetes marker, in whole blood on the ADVIA Chemistry systems. Such measurements are used for monitoring the long-term glycemic control of persons with diabetes. The A1c and total hemoglobin (tHb) values generated as part of the HbA1cN and HbA1cI results are intended for use in the calculation of the A1c / total hemoglobin ratio, and must not be used individually for diagnostic purposes.
*Note: HbA1cN reports HbA1c in % and HbA1cI reports HbA1c in mmol/mol
The ADVIA® Chemistry A1c Calibrators are for in vitro diagnostic use in the calibration of the A1c and total hemoglobin methods (Automated and Manual Pretreatment) on the ADVIA Chemistry Systems.
The concentration of A1c and the concentration of total hemoglobin are measured and the ratio is reported (either as % or mmol/mol).
There are two different sample pretreatment methods available on the ADVIA Chemistry System. The first method is an Automated Pretreatment that uses 4 reagents: A1c Denaturant Reagent, Total Hemoglobin Reagent (tHb 2), A1c Agglutinator Reagent (R1) and A1c Antibody Reagent (R2). In this Automated Pretreatment step, the whole blood sample is mixed with the A1c Denaturant Readent. The red blood cells are lysed and the hemoglobin chains are hydrolyzed by the protease present in the reagent.
The second method is a Manual Pretreatment that uses the same reagents as the first method except that the A1c Denaturant Reagent is replaced with the Hemoglobin Denaturant Reagent. For this method, there is an off-line pretreatment that is followed bv a 10 minute incubation.
For the measurement of total hemoglobin, the Total Hemoglobin Reagent is used. The method is based on the conversion of all hemoglobin derivatives into alkaline hematin in an alkaline solution of a nonionic detergent
A latex agglutination inhibition method is used for the measurement of specific A1c. The A1c present in the sample competes with the agglutinator (synthetic latex containing multiple copies of the immunoreactive portion of A1c) for the anti-A1c antibody; thereby reducing the rate of agglutination. A concentration curve is obtained by monitoring the change in scattered light as a change of absorbance. The actual change in absorbance is inversely proportional to the concentration of A1c in the sample. The HbA1cN NGSP result (%) or the HbA1cl IFCC result (mmol/mol) is calculated using the A1c and total hemoglobin values.
The ADVIA® Chemistry A1c Calibrators are used to calibrate the methods. The calibrators consist of four (4) levels of lyophilized whole blood containing varying concentrations of HbA1c and total hemoglobin. There is a single level calibration for total hemoglobin (Cal 1) and a multi-level calibration (six levels) for A1c. Four calibrator levels (designated Cal 1 - 4) are provided in a single kit and each level is 0.5 g/vial. The other two levels consist of Saline (Cal 0) and Cal 5 (prepared by the system from Cal 4 using 1.4 times the volume used for Cal 4).
The target value of each calibrator (calibration) level is:
- Calibration Level 1 (Cal 0): 0.00 umol/L A1c, 0.0 g/dL Total Hemoglobin ●
- Calibration Level 2 (Cal 1): 2.30 µmol/L A1c, 11.0 g/dL Total Hemoglobin .
- Calibration Level 3 (Cal 2): 3.65 umol/L A1c .
- Calibration Level 4 (Cal 3): 5.15 umol/L A1c .
- Calibration Level 5 (Cal 4): 6.80 umol/L A1c .
- Calibration Level 6 (Cal 5): 8.20 umol/L A1c
The Siemens Healthcare Diagnostics ADVIA® Chemistry Hemoglobin A1c Assay and Calibrators were evaluated for substantial equivalence to predicates. The study demonstrated performance through various tests, including imprecision, method comparison, interfering substances, matrix equivalency, and analytical range.
1. Acceptance Criteria and Reported Device Performance
The provided document does not explicitly state pre-defined acceptance criteria for the performance characteristics. Instead, it presents the results of these performance studies and concludes that they are "acceptable results compared to the Predicate Device" and "support that the ADVIA Chemistry Hemoglobin A1c assay... is substantially equivalent to the Tosoh G7 HPLC Hemoglobin A1c method." However, based on the provided data, we can infer implied acceptance around certain metrics. The performance metrics are reported in comparison to the predicate device or a reference method.
| Performance Metric | Acceptance Criteria (Implied / Compared Against) | Reported Device Performance (ADVIA Chemistry Hemoglobin A1c) |
|---|---|---|
| Imprecision (Total CV) | Comparable to Predicate Device (Tosoh G7 HPLC) | Automated Pretreatment: 1.9% (at 5.5% HbA1c), 1.3% (at 9.6% HbA1c) |
| Manual Pretreatment: 1.9% (at 5.0% HbA1c), 1.4% (at 8.8% HbA1c) | ||
| Predicate Device: 1.12% (at 5.8% HbA1c), 0.71% (at 10.9% HbA1c) | ||
| Method Comparison (Regression) | Correlation with NGSP Reference Method (Tosoh G7) | Automated: $y = 0.98x + 0.17$ ($r = 0.997$, Sy.x = 0.17) (Least Squares) |
| High correlation coefficient (r) close to 1, | Automated: $y = 1.00x + 0.06$ ($r = 1.00$) (Passing Bablok / Pearson's) | |
| slope close to 1, intercept close to 0. | Manual: $y = 0.95x + 0.26$ ($r = 0.995$, Sy.x = 0.19) (Least Squares) | |
| Manual: $y = 0.97x + 0.10$ ($r = 1.00$) (Passing Bablok / Pearson's) | ||
| Interfering Substances (Effect % change) | Minimal effect (specific thresholds not stated, but results considered acceptable) | Triglycerides (500mg/dL): -7.8% (Automated), -7.7% (Manual) |
| Bilirubin, free (60mg/dL): -1.9% (Automated), -2.0% (Manual) | ||
| Bilirubin, conjugated (60mg/dL): -3.8% (Automated), -5.9% (Manual) | ||
| Rheumatoid Factor (1100 IU/mL): 0% (Manual) | ||
| Analytical Range | Stated range the device can accurately measure. | 2.9 - 15.4% |
2. Sample Size Used for the Test Set and Data Provenance
- Sample Size for Method Comparison (Test Set): 80 samples for both Automated and Manual Pretreatment methods.
- Data Provenance: Not explicitly stated (e.g., country of origin). The data appears to be from internal studies conducted by Siemens Healthcare Diagnostics. It is retrospective in the sense that samples were likely collected and then tested, but not explicitly labeled as prospective.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications
Not applicable. This device is an in vitro diagnostic (IVD) assay measuring a biochemical marker (HbA1c). The "ground truth" for the test set in this context is established by a reference method or a predicate device, not by expert interpretation of images or other subjective assessments.
4. Adjudication Method for the Test Set
Not applicable. As this is an IVD assay, ground truth is established by an objective, traceable reference method (NGSP Reference Method, specifically Tosoh G7 in this case), not through expert consensus requiring adjudication.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
Not applicable. This is an in vitro diagnostic device, not an imaging device or AI-assisted diagnostic tool that involves human readers interpreting cases. Therefore, an MRMC study and the concept of human reader improvement with AI assistance are not relevant to this submission.
6. Standalone (Algorithm Only Without Human-in-the-Loop Performance) Study
Yes, the studies presented (imprecision, method comparison, interfering substances, analytical range) demonstrate the standalone performance of the ADVIA Chemistry Hemoglobin A1c Assay. The device directly measures HbA1c concentrations and calculates the ratio, functioning independently of human interpretation of the final measurement.
7. Type of Ground Truth Used
The ground truth used for the method comparison study was established using the NGSP Reference Method (Tosoh G7 Automated HPLC Analyzer - HbA1c Variant Analysis Mode). The document states that the Tosoh G7 is certified by NGSP and used as a reference method for establishing traceable results to the Diabetes Control and Complications Trial (DCCT). This indicates a highly standardized and traceable method for establishing the true HbA1c values.
8. Sample Size for the Training Set
Not explicitly stated. The document focuses on the performance studies (validation) of the finished device. For IVD assays, "training sets" are usually involved in the initial assay development and optimization, rather than being a distinct, reported phase like in AI/ML device development. The calibrators themselves are used to "train" or calibrate the instrument on an ongoing basis.
9. How the Ground Truth for the Training Set was Established
For IVD assays like this, the "ground truth" for calibrators is typically established through a process of assigning traceable values. The ADVIA® Chemistry A1c Calibrators are stated to be "Traceable to NGSP*** and Traceable to IFCC by Master Equation." This means the assigned values for the calibrators are determined through rigorous analytical methods that link them back to internationally recognized standardization programs (NGSP and IFCC), ensuring accuracy and consistency across different laboratories and instruments. This would involve a hierarchy of reference methods and materials.
{0}------------------------------------------------
510(k) Summary
JAN - 8 2009
| Submitter informationContact person: | Philip LiuManager, Regulatory Affairs & Compliance | ||
|---|---|---|---|
| Address: | Siemens Healthcare Diagnostics511 Benedict AvenueTarrytown, NY 10591 | ||
| Phone: | 914-524-2443914-524-2500 (fax) | ||
| Date summary prepared: | November 12, 2008 | ||
| Device Trade or Proprietary Names: | ADVIA® Chemistry Hemoglobin A1c AssayADVIA® Chemistry A1c Calibrators | ||
| Device Common/Usual Name orClassification Name: | Glycosylated Hemoglobin AssayCalibrators | ||
| Classification Number/Class: | LCP / Class II |
JIX / Class II
This 510(k) summary of safety and effectiveness is being submitted in accordance with the requirements of 21 CFR 807.92.
The assigned 510(k) number is: _k081895
Assay Predicate Device:
| Predicate Device | ||
|---|---|---|
| Device Name | G7 Automated HPLC Analyzer - HbA1c Variant Analysis Mode | |
| Common name | Glycosylated Hemoglobin Test | |
| 510(k) Number | K011434 | |
| Manufacturer | Tosoh Medics, Inc. |
Calibrator Predicate Device:
| Predicate Device | ||
|---|---|---|
| Device Name | VITROS Chemistry Products Calibrator Kit 18 | |
| Common name | Calibrator | |
| 510(k) Number | K041764 | |
| Manufacturer | Ortho-Clinical Diagnostics |
Siemens Healthcare Diagnostics (formerly Siemens Medical Solutions Diagnostics) ADVIA Chemistry Hemoglobin A1c Assay and Calibrators Premarket Notification - 510(k) 510(k) Summary
{1}------------------------------------------------
Device Description:
The concentration of A1c and the concentration of total hemoglobin are measured and the ratio is reported (either as % or mmol/mol).
There are two different sample pretreatment methods available on the ADVIA Chemistry System. The first method is an Automated Pretreatment that uses 4 reagents: A1c Denaturant Reagent, Total Hemoglobin Reagent (tHb 2), A1c Agglutinator Reagent (R1) and A1c Antibody Reagent (R2). In this Automated Pretreatment step, the whole blood sample is mixed with the A1c Denaturant Readent. The red blood cells are lysed and the hemoglobin chains are hydrolyzed by the protease present in the reagent.
The second method is a Manual Pretreatment that uses the same reagents as the first method except that the A1c Denaturant Reagent is replaced with the Hemoglobin Denaturant Reagent. For this method, there is an off-line pretreatment that is followed bv a 10 minute incubation.
For the measurement of total hemoglobin, the Total Hemoglobin Reagent is used. The method is based on the conversion of all hemoglobin derivatives into alkaline hematin in an alkaline solution of a nonionic detergent
A latex agglutination inhibition method is used for the measurement of specific A1c. The A1c present in the sample competes with the agglutinator (synthetic latex containing multiple copies of the immunoreactive portion of A1c) for the anti-A1c antibody; thereby reducing the rate of agglutination. A concentration curve is obtained by monitoring the change in scattered light as a change of absorbance. The actual change in absorbance is inversely proportional to the concentration of A1c in the sample. The HbA1cN NGSP result (%) or the HbA1cl IFCC result (mmol/mol) is calculated using the A1c and total hemoglobin values.
The ADVIA® Chemistry A1c Calibrators are used to calibrate the methods. The calibrators consist of four (4) levels of lyophilized whole blood containing varying concentrations of HbA1c and total hemoglobin. There is a single level calibration for total hemoglobin (Cal 1) and a multi-level calibration (six levels) for A1c. Four calibrator levels (designated Cal 1 - 4) are provided in a single kit and each level is 0.5 g/vial. The other two levels consist of Saline (Cal 0) and Cal 5 (prepared by the system from Cal 4 using 1.4 times the volume used for Cal 4).
The target value of each calibrator (calibration) level is:
- Calibration Level 1 (Cal 0): 0.00 umol/L A1c, 0.0 g/dL Total Hemoglobin ●
- Calibration Level 2 (Cal 1): 2.30 µmol/L A1c, 11.0 g/dL Total Hemoglobin .
- Calibration Level 3 (Cal 2): 3.65 umol/L A1c .
- Calibration Level 4 (Cal 3): 5.15 umol/L A1c .
- Calibration Level 5 (Cal 4): 6.80 umol/L A1c .
- Calibration Level 6 (Cal 5): 8.20 umol/L A1c
Siemens Healthcare Diagnostics (formerly Siemens Medical Solutions Diagnostics) ADVIA Chemistry Hemoglobin A1c Assay and Calibrators Premarket Notification - 510(k) 510(k) Summary
{2}------------------------------------------------
Storage is at 2 - 8°C.
CAUTION! POTENTIAL BIOHAZARD: Contains human source material. While each human serum or plasma donor unit used in the manufacture of this product was tested by FDA-approved methods and found nonreactive for hepatitis B surface antigen (HBsAg), antibody to hepatitis C (HCV), and antibody to HIV-1/2, all products manufactured using human source material should be handled as potentially infectious. Because no test method can offer complete assurance that hepatitis B or C viruses, HIV, or other infectious agents are absent, these products should be handled according to established good laboratory practices.
Statement of Intended Use:
The ADVIA® Chemistry Hemoglobin A1c method is for in vitro diagnostic use in the quantitative determination of Hemoglobin A1c, a diabetes marker, in whole blood on the ADVIA Chemistry systems. Such measurements are used for monitoring the long-term alvcemic control of persons with diabetes. The A1c and total hemoglobin (tHb) values generated as part of the HbA1cN and HbA1cl methods are intended for use in the calculation of the A1c / total hemoglobin ratio, and must not be used individually for diagnostic purposes.
*Note: HbA1cN reports HbA1c in % and HbA1cl reports HbA1c in mmol/mol
The ADVIA® Chemistry A1c Calibrators are for in vitro diagnostic use in the calibration of the A1c and total hemoglobin methods (Automated and Manual Pretreatment) on the ADVIA Chemistry Systems.
Comparisons to the Predicate Device:
Method Similarities
| ADVIA ChemistryHemoglobin A1c( new device ) | Tosoh G7 Automated HPLC Analyzer- HbA1c Variant Analysis Mode( predicate device ) | |
|---|---|---|
| Intended Use | For in vitro diagnostic use for themeasurement of hemoglobin A1c | For in vitro diagnostic use for themeasurement of hemoglobin A1c |
| Specimen Type | Human Whole Blood(EDTA and Lithium Heparin) | Human Whole Blood |
| Standardization | Traceable to NGSP***Traceable to IFCC by Master Equation | Traceable to NGSP*** |
{3}------------------------------------------------
Method Differences
| ADVIA ChemistryHemoglobin A1c(new device) | Tosoh G7 Automated HPLC Analyzer- HbA1c Variant Analysis Mode(predicate device) | |
|---|---|---|
| Assay Principle | For Hemoglobin:Conversion of all hemoglobinderivatives into alkaline hematinFor HbA1c:Latex agglutination inhibition | High Performance LiquidChromatography(non-porous ion exchange) |
| Determination /Calculation of results | Ratio of HbA1c/ Total Hemoglobin | Measurement of HbA1c as apercentage of total hemoglobin |
| Calibration | Multipoint calibration (6 levels) forHemoglobin A1cSingle point calibration for TotalHemoglobin | 2 point Calibration (high and low) |
| Analytical Range | 2.9 - 15.4% | 4.2 - 20.8% |
Calibrator Similarities
| ADVIA ChemistryA1c Calibrators(new device) | VITROS Chemistry Products CalibratorKit 18(predicate device) | |
|---|---|---|
| Intended Use | For in vitro diagnostic use in thecalibration of the A1c and totalhemoglobin methods (Automated andManual Pretreatment) on the ADVIAChemistry Systems | For in vitro diagnostic useonly. VITROS Chemistry ProductsCalibrator Kit 18 is used in conjunctionwith VITROS Chemistry Products FSCalibrator 1 to calibrate VITROS 5, 1FS Chemistry Systems for thecalculation of percent glycatedhemoglobin (%A1c). |
| Calibrator Levels | 4 levels provided | 4 levels provided |
| Matrix / Ingredients | Processed human whole blood | Hemolysate derived from human andovine blood, surfactants, stabilizer, andpreservatives |
| Form | Lyophilized | Lyophilized |
| Storage | 2 - 8°C | 2 - 8°C |
| Shelf Life Stability | stable until the expiration date | stable until the expiration date |
| Reconstituted Vial /Use Stability | 7 days stored at 2 - 8°C | 2 days stored at 2 - 8ºC |
Calibrator Differences
| ADVIA ChemistryA1c Calibrators(new device) | VITROS Chemistry Products CalibratorKit 18(predicate device) | |
|---|---|---|
| Instructions for Use(Preparation) | Reconstitute with DI water before use | Reconstitute with diluent before use |
Siemens Healthcare Diagnostics (formerly Siemens Medical Solutions Diagnostics) ADVIA Chemistry Hemoglobin A1c Assay and Calibrators Premarket Notification - 510(k) 510(k) Summary .
{4}------------------------------------------------
Performance:
Substantial equivalence was demonstrated by testing several performance characteristics including imprecision, method comparison, interfering substances, matrix equivalency, and analytical range. The following tables summarize the precision (total), interfering substances, analytical range, and method comparison results.
All of the evaluation studies gave acceptable results compared to the Predicate Device. These studies support that the ADVIA Chemistry Hemoglobin A1c assay (with the ADVIA Chemistry A1c Calibrators) is substantially equivalent to the Tosoh G7 HPLC Hemoglobin A1c method that is currently marketed.
Imprecision
| ADVIA ChemistryHemoglobin A1cADVIA 1800 - Automated | ADVIA ChemistryHemoglobin A1cADVIA 1800 - Manual | Tosoh G7 HPLCHbA1c | |||
|---|---|---|---|---|---|
| LevelHbA1c (%) | Total CV(%) | LevelHbA1c (%) | Total CV(%) | LevelHbA1c (%) | Total CV(%) |
| 5.5 | 1.9 | 5.0 | 1.9 | 5.8 | 1.12 |
| 9.6 | 1.3 | 8.8 | 1.4 | 10.9 | 0.71 |
Correlation
(y = ADVIA Chemistry Hemoglobin A1c, x = comparison method/system)
| System (y) | N | RegressionEquation | r | Sy.x | Sample Range(%) |
|---|---|---|---|---|---|
| ADVIA 1800 Automated –Least Squares | 80 | $y = 0.98x + 0.17$ | 0.997 | 0.17 | 4.40 - 12.60 |
| ADVIA 1800 Automated –Passing Bablok / Pearson's | 80 | $y = 1.00x + 0.06$ | 1.00 | -- | 4.40 - 12.60 |
| ADVIA 1800 Manual –Least Squares | 80 | $y = 0.95x + 0.26$ | 0.995 | 0.19 | 4.40 - 12.60 |
| ADVIA 1800 Manual –Passing Bablok / Pearson's | 80 | $y = 0.97x + 0.10$ | 1.00 | -- | 4.40 - 12.60 |
x = NGSP Reference Method (Tosoh G7), y = ADVIA Chemistry System
Interfering Substances (ADVIA Chemistry Hemoglobin A1c on ADVIA 1800)
Automated Sample Pretreatment
| Interfering Substance | Interferent Conc.(mg/dL) | HbA1c conc.(%) | Effect(% change) |
|---|---|---|---|
| Triglycerides (Intralipid) | 500 mg/dL | 5.2 | - 7.8 |
| Bilirubin, free | 60 mg/dL | 5.3 | - 1.9 |
| Bilirubin, conjugated | 60 mg/dL | 5.2 | - 3.8 |
Siemens Healthcare Diagnostics (formerly Siemens Medical Solutions Diagnostics) ADVIA Chemistry Hemoglobin A1c Assay and Calibrators Premarket Notification - 510(k) 510(k) Summary
Page 5 of 6
{5}------------------------------------------------
Manual Sample Pretreatment
| Interfering Substance | Interferent Conc.(mg/dL) | HbA1c conc.(%) | Effect(% change) |
|---|---|---|---|
| Triglycerides (Intralipid) | 500 mg/dL | 5.2 | - 7.7 |
| Bilirubin, free | 60 mg/dL | 5.1 | - 2.0 |
| Bilirubin, conjugated | 60 mg/dL | 5.1 | - 5.9 |
| Rheumatoid Factor | 1100 IU/mL | 4.8 | 0 |
Analytical Range
| Platform | Analytical Range | ||
|---|---|---|---|
| All ADVIA Chemistry ' ' | - Galibrator Leval 6-(12-3-18.6%)1 -1 -1 -1 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- 2 -- | 2.4 /0 - | 10 |
Conclusions:
The ADVIA Chemistry Hemoglobin A1c method and Calibrators are substantially equivalent to other products in commercial distribution intended for similar use. Most notably, it is substantially equivalent to the currently marketed Tosoh G7 Automated HPLC Analyzer- HbA1c Variant Analysis Mode. The Tosoh G7 Automated HPLC Analyzer is certified by the National Glycohemoglobin Standardization Program (NGSP) and it is used as a reference method for establishing traceable results of other methods to the Diabetes Control and Complications Trial (DCCT).
The ADVIA Chemistry A1c Calibrators are substantially equivalent to the Predicate Device VITROS Chemistry Products Calibrator Kit 18.
{6}------------------------------------------------
Image /page/6/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an emblem featuring a stylized eagle with its wings spread, symbolizing the department's mission to protect the health of all Americans.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Siemens Healthcare Diagnostic c/o Dr. Philip Liu Manager, Regulatory Affairs and Compliance 511 Benedict Avenue Tarrytown, NY 10591
JAN - 8 2009
K081895 Re:
Trade/Device Name: ADVIA Chemistry Hemoglobin A1c Assay, ADVIA Chemistry
Alc Calibrators
Regulation Number: 21 CFR 864.7470 Regulation Name: Glycosylate hemoglobin assay. Regulatory Class: Class II Product Code: LCP, JIX Dated: November 18, 2008 Received: November 19, 2008
Dear Dr. Liu:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820).
{7}------------------------------------------------
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Gregory C. Hammett, Ph.D.
Courthey C. Harper, Ph.D. Acting Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{8}------------------------------------------------
Indication for Use
510(k) Number (if known): K081895
Device Name(s):
ADVIA® Chemistry Hemoglobin A1c ADVIA® Chemistry A1c Calibrators
Indications For Use:
The ADVIA® Chemistry Hemoglobin A1c method is for in vitro diagnostic use in the quantitative determination of Hemoglobin A1c, a diabetes marker, in whole blood on the ADVIA Chemistry systems. Such measurements are used for monitoring the long-term glycemic control of persons with diabetes. The A1c and total hemoglobin (tHb) values generated as part of the HbA1cN and HbA1cI results are intended for use in the calculation of the A1c / total hemoglobin ratio, and must not be used individually for diagnostic purposes.
*Note: HbA1cN reports HbA1c in % and HbA1cI reports HbA1c in mmol/mol
The ADVIA® Chemistry A1c Calibrators are for in vitro diagnostic use in the calibration of the A1c and total hemoglobin methods (Automated and Manual Pretreatment) on the ADVIA Chemistry Systems.
Prescription Use X (21 CFR Part 801 Subpart D)
And/Or
Over the Counter Use (21 CFR Part 801 Subpart C),
(PLEASE DO NOT WRITE BELOW THIS LINE: CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)
Carol C. Benson
Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K081895
§ 864.7470 Glycosylated hemoglobin assay.
(a)
Identification. A glycosylated hemoglobin assay is a device used to measure the glycosylated hemoglobins (A1a , A1b , and A1c ) in a patient's blood by a column chromatographic procedure. Measurement of glycosylated hemoglobin is used to assess the level of control of a patient's diabetes and to determine the proper insulin dosage for a patient. Elevated levels of glycosylated hemoglobin indicate uncontrolled diabetes in a patient.(b)
Classification. Class II (performance standards).